Bactiguard appoints Gabriella Björknert Caracciolo as new CFO
Bactiguard Holding AB (publ) has appointed Gabriella Björknert Caracciolo, currently Head of Strategy, Development and Governance within Transaction Banking, Nordea as new CFO and Executive Vice President. She succeeds Cecilia Edström, who in February was appointed CEO of the company. Gabriella Björknert Caracciolo assumes her new position in August 2020.
“Gabriella Caracciolo is an experienced and development oriented leader with a strong business focus and broad experience. Her financial skills are solid, and she has extensive experience in driving business transformations. These are valuable qualities in the process of taking Bactiguard to the next level. I am therefore very pleased that we succeeded in recruiting Gabriella to Bactiguard and look forward to working closely with her in the management team,” says Cecilia Edström, CEO.
“I am honoured to succeed Cecilia and looking forward to joining the Bactiguard management team and contributing to their efforts in saving lives. Bactiguard has built a solid foundation and has a fantastic growth potential,” says Gabriella Björknert Caracciolo.
Gabriella Björknert Caracciolo is currently Head of Strategy, Development and Governance within Transaction Banking, Nordea and has been employed by the bank since 2016. Prior to that she held a number of different leading positions within Skandinaviska Enskilda Banken (SEB), with focus on strategy, business development and IT for a period of twelve years. Gabriella is 49 years old, holds a Master of Business Administration degree from the Stockholm University and started her professional life as a management consultant.
In her role as CFO, Gabriella will be responsible for finance, IT, HR and business development.
Lina Arverud will maintain the role of acting CFO until Gabriella takes office and will then return to her regular role as Financial Manager.
For further information, please contact:
Cecilia Edström, CEO: +46 8 440 58 80
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.
Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.
Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com
Tags:
